Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Fibrodysplasia Ossificans Progressiva Pipeline Drugs Market
Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside that constrains movement. Symptoms swellings in fibrous tissue, pain, fever, muscle ossification, and restricted movement of joints. Treatment includes surgery and medications to help relieve symptoms of FOP, such as pain and inflammation.
The FOP pipeline products market research report provides comprehensive information on the therapeutics under development for FOP, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for FOP and features dormant and discontinued projects.
FOP Pipeline Products Market Segmentation by Targets
The key targets in the FOP pipeline products market are Activin Receptor Type 1, Retinoic Acid Receptor Gamma, Growth/Differentiation Factor 8, Inhibin Beta A Chain, Proto Oncogene Tyrosine Protein Kinase Src, Serine/Threonine Protein Kinase mTOR, Tyrosine Protein Kinase ABL1, and Tyrosine Protein Kinase Fyn. Activin Receptor Type 1 is the leading target in the FOP pipeline products market.
FOP Pipeline Products Market Analysis by Targets
For more target insights into the FOP pipeline products market, download a free report sample
FOP Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the FOP pipeline products market are Activin Receptor Type 1 Inhibitor, Retinoic Acid Receptor Gamma Agonist, Activin Receptor Type 1 Antagonist, Growth/Differentiation Factor 8 Inhibitor, Inhibin Beta A Chain Inhibitor, Proto Oncogene Tyrosine Protein Kinase Src Inhibitor, Serine/Threonine Protein Kinase mTOR Inhibitor, Tyrosine Protein Kinase ABL1 Inhibitor, and Tyrosine Protein Kinase Fyn Inhibitor. Activin Receptor Type 1 Inhibitor is the leading MoA in the pipeline market.
FOP Pipeline Products Market Analysis by Mechanisms of Action
For more MoA insights into the FOP pipeline products market, download a free report sample
FOP Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the FOP pipeline products market are oral, ophthalmic, subcutaneous, intravenous, and topical. Oral accounted for the highest number of FOP drugs in development in terms of RoA, in 2022.
FOP Pipeline Products Market Analysis by Routes of Administration
For more RoA insights into the FOP pipeline products market, download a free report sample
FOP Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the FOP pipeline products market are small molecule, monoclonal antibody, and antibody. The small molecule is the leading molecule type in the FOP pipeline drugs market.
FOP Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the FOP pipeline products market, download a free report sample
FOP Pipeline Products Market - Competitive Landscape
Some of the leading companies in the FOP pipeline products market are Regeneron Pharmaceuticals Inc, Ipsen SA, La Jolla Pharmaceutical Company, AstraZeneca Plc, Clementia Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Incyte Corp, and Pfizer Inc. Regeneron Pharmaceuticals Inc is the leading company in the FOP pipeline products market.
FOP Pipeline Products Market Analysis by Companies
To know more about the leading FOP pipeline products market players, download a free report sample
FOP Pipeline Products Market Overview
| Key Targets | Activin Receptor Type 1, Retinoic Acid Receptor Gamma, Growth/Differentiation Factor 8, Inhibin Beta A Chain, Proto Oncogene Tyrosine Protein Kinase Src, Serine/Threonine Protein Kinase mTOR, Tyrosine Protein Kinase ABL1, and Tyrosine Protein Kinase Fyn |
| Key MoA | Activin Receptor Type 1 Inhibitor, Retinoic Acid Receptor Gamma Agonist, Activin Receptor Type 1 Antagonist, Growth/Differentiation Factor 8 Inhibitor, Inhibin Beta A Chain Inhibitor, Proto Oncogene Tyrosine Protein Kinase Src Inhibitor, Serine/Threonine Protein Kinase mTOR Inhibitor, Tyrosine Protein Kinase ABL1 Inhibitor, and Tyrosine Protein Kinase Fyn Inhibitor |
| Key RoA | Oral, Ophthalmic, Subcutaneous, Intravenous, and Topical |
| Key Molecule Type | Small Molecule, Monoclonal Antibody, and Antibody |
| Leading Companies | Regeneron Pharmaceuticals Inc, Ipsen SA, La Jolla Pharmaceutical Company, AstraZeneca Plc, Clementia Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Incyte Corp, and Pfizer Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of FOP.
- The pipeline guide reviews pipeline therapeutics for FOP by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in FOP therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates FOP therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for FOP
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for FOP.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the FOP pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Clementia Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Incyte Corp
Ipsen SA
La Jolla Pharmaceutical Company
Pfizer Inc
Regeneron Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the FOP pipeline products market?
The key targets in the FOP pipeline products market are Activin Receptor Type 1, Retinoic Acid Receptor Gamma, Growth/Differentiation Factor 8, Inhibin Beta A Chain, Proto Oncogene Tyrosine Protein Kinase Src, Serine/Threonine Protein Kinase mTOR, Tyrosine Protein Kinase ABL1, and Tyrosine Protein Kinase Fyn.
-
What are the key mechanisms of action in the FOP pipeline products market?
The key MoA in the FOP pipeline products market are Activin Receptor Type 1 Inhibitor, Retinoic Acid Receptor Gamma Agonist, Activin Receptor Type 1 Antagonist, Growth/Differentiation Factor 8 Inhibitor, Inhibin Beta A Chain Inhibitor, Proto Oncogene Tyrosine Protein Kinase Src Inhibitor, Serine/Threonine Protein Kinase mTOR Inhibitor, Tyrosine Protein Kinase ABL1 Inhibitor, and Tyrosine Protein Kinase Fyn Inhibitor.
-
What are the key routes of administration in the FOP pipeline products market?
The key RoA in the FOP pipeline products market are oral, ophthalmic, subcutaneous, intravenous, and topical.
-
What are the key molecule types in the FOP pipeline products market?
The key molecule types in the FOP pipeline products market are small molecule, monoclonal antibody, and antibody.
-
Which are the leading companies in the FOP pipeline products market?
Some of the leading companies in the FOP pipeline products market are Regeneron Pharmaceuticals Inc, Ipsen SA, La Jolla Pharmaceutical Company, AstraZeneca Plc, Clementia Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Incyte Corp, and Pfizer Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Musculoskeletal Disorders reports